COSCIENS Biopharma Inc.

AI-generated fair value estimate for this company.

Method: Sum-of-parts/net-asset approach: cash $5.3M (June 30, 2026) plus continuing-operations revenue (~$12.4M annualized, +29% YoY) valued at a conservative 0.5x revenue (~$6.2M), for ~$11.5M total, divided by ~1.05M shares outstanding (implied from reported H1-2026 EPS).

Reasoning: Reported net income is dominated by one-off divestiture gains from a serially-restructuring business, so an earnings-based DCF would be misleading; an asset/revenue-based approach better reflects the shrinking business, though confidence is low given inconsistent share-count data across sources post-restructuring.